Abstract
In patients with myelofibrosis (MF), allogeneic stem cell transplantation (SCT) is a curative treatment, but does entail risk of treatment-related mortality (TRM). Furthermore, a minority of patients cured of myelofibrosis are at risk of chronic graft-versus-host disease (GvHD) that may impair their quality of life. It is also pertinent to note that transplant early in the disease course results in better transplant outcome than transplant late in the disease course.1 Thus, the survival benefit of SCT needs to be weighed against early transplant related mortality (TRM) and morbidity, as well as impaired quality of life due to chronic GvHD, when deciding about timing of transplant in the natural history of disease.
Original language | English (US) |
---|---|
Pages (from-to) | S19 |
Journal | Clinical Lymphoma, Myeloma and Leukemia |
Volume | 20 |
DOIs | |
State | Published - Sep 2020 |
Externally published | Yes |
Keywords
- Allogeneic hematopoietic stem cell transplant
- intermediate-1 risk transplant in young
- myeloproliferative disorder
- symptomatic myelofibrosis
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research